[go: up one dir, main page]

CO5180590A1 - Derivados de camptotecina que tienen actividad anti tumores - Google Patents

Derivados de camptotecina que tienen actividad anti tumores

Info

Publication number
CO5180590A1
CO5180590A1 CO00016957A CO00016957A CO5180590A1 CO 5180590 A1 CO5180590 A1 CO 5180590A1 CO 00016957 A CO00016957 A CO 00016957A CO 00016957 A CO00016957 A CO 00016957A CO 5180590 A1 CO5180590 A1 CO 5180590A1
Authority
CO
Colombia
Prior art keywords
derivatives
camptotechine
formula
tumors
compounds
Prior art date
Application number
CO00016957A
Other languages
English (en)
Inventor
Paolo Carminati
Sergio Penco
Lucio Merlini
Franco Zunino
Original Assignee
Sigma Tau Ind Farmaceuti
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Ist Naz Stud Cura Dei Tumori filed Critical Sigma Tau Ind Farmaceuti
Publication of CO5180590A1 publication Critical patent/CO5180590A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan derivados de camptotecina de camptotecina de fórmula (I)<EMI FILE="00016957_1" ID="1" IMF=JPEG >donde los grupos R1, R2, y R3 son como se definió en la descripción.Los compuestos de fórmula (I) están dotados con actividad anti-tumores y muestran un buen índice terapéutico.También se divulgan procesos para la preparación de los compuestos de fórmula (I) y su uso en la preparación de medicamentos útiles en el tratamiento de tumores, infecciones virales y antiplasmodium alciparum.
CO00016957A 1999-03-09 2000-03-08 Derivados de camptotecina que tienen actividad anti tumores CO5180590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity

Publications (1)

Publication Number Publication Date
CO5180590A1 true CO5180590A1 (es) 2002-07-30

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00016957A CO5180590A1 (es) 1999-03-09 2000-03-08 Derivados de camptotecina que tienen actividad anti tumores

Country Status (39)

Country Link
US (2) US6242457B1 (es)
EP (1) EP1044977B1 (es)
JP (1) JP4610743B2 (es)
KR (1) KR100702085B1 (es)
CN (1) CN1139592C (es)
AR (1) AR022860A1 (es)
AT (1) ATE216998T1 (es)
AU (1) AU774174B2 (es)
BG (1) BG65032B1 (es)
BR (1) BR0008840B1 (es)
CA (1) CA2362760C (es)
CO (1) CO5180590A1 (es)
CZ (1) CZ304465B6 (es)
DE (1) DE69901379T2 (es)
DK (1) DK1044977T3 (es)
EA (1) EA003605B1 (es)
EE (1) EE04679B1 (es)
EG (1) EG23999A (es)
ES (1) ES2175919T3 (es)
HK (1) HK1031222A1 (es)
HR (1) HRP20010667B1 (es)
HU (1) HU229506B1 (es)
IL (2) IL144958A0 (es)
IS (1) IS2003B (es)
ME (2) MEP4008A (es)
MX (1) MXPA01009081A (es)
NO (1) NO328363B1 (es)
NZ (1) NZ513393A (es)
PE (1) PE20001485A1 (es)
PL (1) PL222208B1 (es)
PT (1) PT1044977E (es)
RS (1) RS50405B (es)
SI (1) SI1044977T1 (es)
SK (1) SK287561B6 (es)
TN (1) TNSN00045A1 (es)
TR (1) TR200102603T2 (es)
TW (1) TWI272272B (es)
WO (1) WO2000053607A1 (es)
ZA (1) ZA200107408B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376824T1 (de) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
EP1427447A4 (en) * 2001-08-27 2007-05-23 Alchemia Oncology Ltd IMPROVED THERAPEUTIC PROTOCOLS
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
AU2005226932B2 (en) * 2004-03-26 2009-07-09 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9-硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
CA2589521C (en) * 2004-12-15 2014-04-01 Novartis Ag Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
BRPI0515832A (pt) 2004-12-21 2008-08-05 Sigma Tau Ind Farmaceuti processo estereosseletivo e formas cristalinas de uma camptotecina
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
AU2006274509B2 (en) * 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
CN101232872A (zh) * 2005-08-10 2008-07-30 诺瓦提斯公司 7-(叔丁氧基)亚氨基甲基喜树碱的制剂
EP2772260A3 (en) * 2005-09-07 2014-10-15 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US7888368B2 (en) * 2005-12-21 2011-02-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors
WO2007098091A2 (en) * 2006-02-17 2007-08-30 Novacea, Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
KR101394768B1 (ko) 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
EP2107903A1 (en) * 2007-02-01 2009-10-14 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical composition comprising a campothecin derivative
EP2120948A1 (en) * 2007-02-13 2009-11-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
BRPI0815051A2 (pt) * 2007-08-01 2015-02-10 Sigma Tau Ind Farmaceuti Tratamento de tumores pediátricos
EP2096113A1 (en) * 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
WO1993009782A1 (en) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
BR9711319B1 (pt) * 1996-08-19 2009-08-11 derivados de camptotecina altamente lipofìlicos.

Also Published As

Publication number Publication date
AR022860A1 (es) 2002-09-04
TR200102603T2 (tr) 2002-01-21
EE04679B1 (et) 2006-08-15
NZ513393A (en) 2003-04-29
TNSN00045A1 (fr) 2005-11-10
SK11642001A3 (sk) 2002-01-07
BR0008840A (pt) 2002-01-08
BG105810A (en) 2002-06-28
ME00017B (me) 2010-06-10
US6589939B2 (en) 2003-07-08
ATE216998T1 (de) 2002-05-15
HRP20010667B1 (en) 2003-06-30
US20010008939A1 (en) 2001-07-19
SK287561B6 (sk) 2011-02-04
EG23999A (en) 2008-03-19
CA2362760C (en) 2009-08-18
JP4610743B2 (ja) 2011-01-12
MEP4008A (xx) 2010-02-10
PL222208B1 (pl) 2016-07-29
DK1044977T3 (da) 2002-07-08
BR0008840B1 (pt) 2011-12-27
HU229506B1 (en) 2014-01-28
IS6031A (is) 2001-07-31
EP1044977B1 (en) 2002-05-02
AU3160400A (en) 2000-09-28
YU64301A (sh) 2005-07-19
HK1031222A1 (en) 2001-06-08
CN1139592C (zh) 2004-02-25
MXPA01009081A (es) 2002-08-30
AU774174B2 (en) 2004-06-17
RS50405B (sr) 2009-12-31
CA2362760A1 (en) 2000-09-14
EA003605B1 (ru) 2003-06-26
TWI272272B (en) 2007-02-01
EA200100954A1 (ru) 2002-04-25
BG65032B1 (bg) 2006-12-29
WO2000053607A1 (en) 2000-09-14
EE200100466A (et) 2002-12-16
IL144958A (en) 2009-08-03
NO20014128L (no) 2001-08-24
CZ20013077A3 (cs) 2002-01-16
IL144958A0 (en) 2002-06-30
DE69901379T2 (de) 2002-11-07
IS2003B (is) 2005-04-15
HUP0200210A3 (en) 2004-03-29
ES2175919T3 (es) 2002-11-16
ZA200107408B (en) 2002-05-29
CZ304465B6 (cs) 2014-05-21
US6242457B1 (en) 2001-06-05
EP1044977A1 (en) 2000-10-18
JP2002539128A (ja) 2002-11-19
PE20001485A1 (es) 2000-12-07
HUP0200210A2 (hu) 2002-05-29
CN1343209A (zh) 2002-04-03
HRP20010667A2 (en) 2002-08-31
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
PL355094A1 (en) 2004-03-22
KR100702085B1 (ko) 2007-04-02
NO20014128D0 (no) 2001-08-24
KR20010102519A (ko) 2001-11-15
DE69901379D1 (de) 2002-06-06
SI1044977T1 (en) 2002-08-31

Similar Documents

Publication Publication Date Title
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
AR027059A1 (es) Bases de mannich indolicas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
SE9504661D0 (sv) New compounds
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2132216T3 (es) Nuevos derivados de amidinas, su preparacion y utilizacion como medicamentos con efecto antagonista de ltb4.
IT1311923B1 (it) Composti farmaceutici.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
ES2153820T3 (es) Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones.
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
SE0003476D0 (sv) Compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE60315288D1 (de) Cyanoguanidin prodrugs
SE9504662D0 (sv) New compounds
MXPA03003798A (es) Derivados triciclicos de indol con actividad antiangiogenica.
TW200504076A (en) 7-imino derivatives camptothecin having antitumor activity
UY26498A1 (es) Pirroles sustituidos
BRPI0414319A (pt) agentes antibacterianos de quinolona
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso

Legal Events

Date Code Title Description
FG Application granted